Baseline co-occurring mutation analysis. (A) Heat map showing co-occurring mutations at baseline by best overall response category (NGS; whole bone marrow; n = 167 patients). Merge of dose-escalation and dose-expansion data (VAF cutoff, 1%-5%). Cytogenetic risk was classified according to the National Comprehensive Cancer Network Clinical Practice Guidelines for AML, version 1.2015. The bar graph depicts the frequency of genes with co-occurring mutations. A similar heat map with detected mutations by VAF level is provided in supplemental Figure 1. (B) Association between mutation status and best response. P value is based on Fisher’s exact test examining the association between specific pathway or gene mutations and best overall response of CR/CRh vs non-CR/CRh responders and nonresponders. NC denotes P value not calculated because of small number of patients with mutation. FLT3-TKD⁺ denotes FLT3-TKD or juxtamembrane domain point mutations. Data source: 167 patients with baseline NGS data from whole bone marrow. IDH1-MC, IDH1 mutation clearance; ITD, internal tandem duplication; mut, mutant; wt, wild-type.